Summary & Overview
CPT 0209U: Genome-wide CNV and Structural Variation Analysis (CNGnome™)
Headline: CPT code 0209U: Genome-wide CNV and structural variation analysis (CNGnome™)
Lead: CPT code 0209U represents a Proprietary Laboratory Analyses (PLA) test — the CNGnome™ assay from PerkinElmer Genomics — that evaluates the entire genome for copy number variants and other chromosomal abnormalities. The code standardizes billing for a single manufacturer-specific genomic test with implications for diagnostic workflows and payer coverage decisions nationwide.
What this code represents and why it matters: CPT code 0209U designates a single-vendor, high-complexity genomic assay focused on genome-wide CNV detection and structural variant characterization. Genome-wide CNV testing can inform diagnosis for developmental disorders, congenital anomalies, and other conditions tied to chromosomal imbalance, making coverage and coding clarity important for clinical genetics and specialty laboratories.
Key payers covered: The analysis addresses national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication provides benchmarks and contextual information on clinical use, coding interpretation for a PLA test, and payer coverage considerations. Readers will find a concise description of the test’s clinical purpose, typical laboratory setting, and the role of CPT PLA coding in distinguishing vendor-specific assays. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 0209U is a Proprietary Laboratory Analyses (PLA) code that describes the CNGnome™ test by PerkinElmer Genomics. The test evaluates a patient’s entire genome for copy number variants (CNVs) and other chromosomal markers of abnormality, including structural changes and regions of homozygosity.
Service Type: Comprehensive genomic analysis for copy number and structural variation
Typical Site of Service: Clinical diagnostic laboratory
Clinical & Coding Specifications
Clinical Context
A pediatric or adult patient with unexplained developmental delay, intellectual disability, congenital anomalies, multiple congenital malformations, autistic features, or suspected chromosomal disorder is referred for comprehensive genomic copy number analysis. The ordering clinician (often a medical geneticist, pediatrician, neurologist, or maternal–fetal medicine specialist) documents the clinical indications and obtains informed consent for genome‑wide copy number variant analysis. A blood sample (or other validated specimen such as saliva or tissue when indicated) is collected at an outpatient clinic, hospital, or prenatal diagnostic center and sent to the PerkinElmer Genomics laboratory.
The laboratory performs the CNGnome™ test (0209U) to evaluate genome‑wide copy number variants, structural chromosomal abnormalities, and regions of homozygosity. The testing workflow includes specimen accessioning, DNA extraction, quality control, genome analysis using proprietary platforms and bioinformatics, variant interpretation by laboratory molecular geneticists, and a finalized report returned to the ordering clinician. Results inform diagnosis, management, recurrence risk counseling, and may guide further targeted testing or referral to genetic counseling. Typical sites of service include outpatient clinics, inpatient hospital wards, prenatal diagnostic centers, and reference laboratory facilities.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |